EARNING RECAP

Oracle

#ORCL 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q2 adjusted 80c est. 78c $9.6B est. $9.52B +.26% ($45.85 closing price) $48.34 $45.44 Q2 cloud services & support revenue $6.6B, FREE cash flow grew 10% to $13.8B; Q2 adjusted operating margin 43%; sees Q3 adjusted EPS 86c-88c, est. 84c, sees Q3 revenue growth 2%- 4% est. $9.85B
Q1 adjusted 71c est. 69c $9.2B est. $9.31B -.31% ($49.03 closing) $49.54 $47.36 raises share repurchase authorization by $12B; sees Q2 adjusted EPS 77c -79c est. 79c; says SaaS PaaS pipeline at record level;
#ORCL 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted 99c est. 94c $11.3B est. $11.19B -7.45% ($42.82 closing) $44.79 $42.57 CEO Katz says Cloud revenue becoming larger %tile of overall revenue; sees Q1 adjusted EPS 67c-69c est. 72c; sees Fy19 revenue higher than 2018 est. at $41.02B
Q3 adjusted 83c vs 72c $9.8B vs $9.78B -10% closing at $47.05 47.75 46.43 sees Q4 adjusted EPS 92c-95c vs 90c
Q2 adjusted EPS 70c est. 68c $9.63B est. $9.57B -3.77% ($48.30 closing price) 48.48 47 increases authorization stocks repurchase by $12B.
Q1 adjusted EPS 62c est. 60c $9.21B est. $9.03B -7.67% ($48.74 closing price) 50.70 48.48

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.